Leo Pharma AS - Strategic SWOT Analysis Review

May 2019 | 44 pages | ID: L1D4ED8D4E3EN
GlobalData

Abstracts

Leo Pharma AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

LEO Pharma AS (LEO Pharma), a subsidiary of LEO Foundation is a research-based pharmaceutical company. It discovers, develops, manufactures and commercializes pharmaceutical products in therapeutic areas dermatology and thrombosis. The company focuses on the treatment of diseases such as psoriasis, eczema, skin infections, actinic keratosis, non-melanoma skin cancer and thrombosis. It also manufactures and markets products for the treatment of diseases in the areas of cardiovascular, bacterial infections, coagulation, osteoporosis and renal problems. LEO Pharma markets its products worldwide and has presence in Europe, the Middle East, Africa, Asia, the Americas and Oceania. LEO Pharma is headquartered in Ballerup, Denmark.

Leo Pharma AS Key Recent Developments

May 10,2019: LEO Pharma strengthens US footprint and global development team with appointment of vice presidents for global regulatory affairs and global project management
Apr 11,2019: LEO Pharma and Research Project BIOMAP: Towards personalised medicine for inflammatory skin diseases
Mar 26,2019: LEO pharma standardizes on veeva development cloud to speed drug development
Feb 28,2019: Olivier Bohuon elected new chairman of LEO Pharma's Board of Directors
Feb 28,2019: LEO Pharma: Annual Results 2018

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Leo Pharma AS - Key Facts
Leo Pharma AS - Key Employees
Leo Pharma AS - Key Employee Biographies
Leo Pharma AS - Major Products and Services
Leo Pharma AS - History
Leo Pharma AS - Company Statement
Leo Pharma AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Leo Pharma AS - Business Description
Product Category: Eczema and Skin Infection
Performance
Product Category: Actinic Keratosis
Overview
Performance
Product Category: Eczema and Skin Infection
Overview
Product Category: Other
Overview
Performance
Product Category: Psoriasis
Overview
Performance
Product Category: Thrombosis
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: International
Performance
Geographical Segment: US
Performance
R&D Overview
Leo Pharma AS - Corporate Strategy
Leo Pharma AS - SWOT Analysis
SWOT Analysis - Overview
Leo Pharma AS - Strengths
Leo Pharma AS - Weaknesses
Leo Pharma AS - Opportunities
Leo Pharma AS - Threats
Leo Pharma AS - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Leo Pharma AS, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

May 10, 2019: LEO Pharma strengthens US footprint and global development team with appointment of vice presidents for global regulatory affairs and global project management
Apr 11, 2019: LEO Pharma and Research Project BIOMAP: Towards personalised medicine for inflammatory skin diseases
Mar 26, 2019: LEO pharma standardizes on veeva development cloud to speed drug development
Feb 28, 2019: Olivier Bohuon elected new chairman of LEO Pharma's Board of Directors
Feb 28, 2019: LEO Pharma: Annual Results 2018
Jan 28, 2019: LEO Pharma appoints Thomas Hultsch as head of Translational Medicine
Jan 09, 2019: LEO Pharma strengthens focus on Translational Medicine with the appointment of Adam B. Raff as Director and Medical Advisor
Sep 17, 2018: Morphosys and LEO Pharma expand strategic alliance to develop peptide-derived therapeutics
Sep 12, 2018: LEO Pharma to showcase two dozen data presentations at 27th Annual European Academy of Dermatology and Venerology Congress in Paris
Sep 06, 2018: LEO Pharma closes Bayer’s prescription dermatology unit deal in US

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Leo Pharma AS, Key Facts
Leo Pharma AS, Key Employees
Leo Pharma AS, Key Employee Biographies
Leo Pharma AS, Major Products and Services
Leo Pharma AS, History
Leo Pharma AS, Subsidiaries
Leo Pharma AS, Key Competitors
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Leo Pharma AS, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

UCB SA
GlaxoSmithKline AS
Galderma SA
Celgene ApS
Bausch Health Companies Inc
ALK-Abello AS